Skip to main content

Table 1 Patient characteristics and clinicopathological variables for each of three cohorts

From: ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

Patient characteristics Cohort 1 Cohort 2 Cohort 3
  n = 184 n = 68 n = 177
median age (range) 58 (28–87) 60 (27–82) 68 (48–89)
Histology    
Ductal 138 (75.0%) 52 (76.5%) 143 (80.8%)
Lobular 28 (15.2%) 0 16 (9.0%)
Other 18 (9.8%) 16 (23.5%) 18 (10.2%)
Receptor status    
ERpos/PRpos or unknown 143 (77.3%) 0 177 (100%)
ERpos/PRneg 27 (14.6%) 0 0
ERneg/PRneg 14 (8.1%) 68 (100%) 0
Her2 status    
positive 27 (14.7%) 0 15 (8.5%)
negative 145 (78.8%) 68 (100%) 160 (90.4%)
unknown 12 (6.5%) 0 2 (1.1%)
Max tumor dimension    
0.1-2.0 cm 115 (62.5%) 42 (61.8%)  
2.1-5.0 cm 51 (27.6%) 21 (30.9%)  
5.1+ cm 18 (9.7%) 5 (7.4%) *
Number of positive nodes    
0 112 (60.9%) 49 (73.5%) 110 (62.1%)
1-3 46 (25.0%) 14 (20.6%) 47 (26.6%)
4-9 16 (8.7%) 3 (4.4%) 13 (7.3%)
10+ 10 (5.4%) 1 (1.5%) 7 (4.0%)
unknown 0 1 (1.5%) 0
Nuclear Grade 3 45 (24.5%) 55 (80.9%) 41 (23.2%)
max Ki67 across all cores    
not done 3 (1.6%) 6 (8.7%) 177 (100%)
0 – 10% 61 (33.2%) 16 (23.2%)
10.1 – 25% 59 (32.1%) 9 (13.0%)
25.1 – 50% 40 (21.7%) 6 (8.7%)
50.1-100% 21 (11.4%) 32 (46.4%)
ERβ1 nuclear expression   
negative/low (0–2) 121 (65.7%) 51 (75.0%) 32 (18.1%)
moderate (3–5) 59 (32.1%) 17 (25.0%) 96 (54.2%)
high (6–7) 4 (2.2%) 0 49 (27.7%)
ERβ1 cytoplasmic expression    
negative/low (0–2) 164 (89.1%) 45 (66.2%) 1 (0.6%)
moderate (3–5) 20 (10.9%) 21 (30.9%) 52 (29.4%)
high (6–7) 0 2 (2.9%) 124 (70.1%)
  1. *tumor size collected as < 3 m vs. ≥ 3 cm: 140 (79.1%) vs. 37 (20.5%).
\